Using CPAP in COVID-19 patients outside of the intensive care setting: a comparison of survival and outcomes between dialysis and non-dialysis dependent patients.
Lauren FloydMadelena StaussJoshua StorrarParthvi VanaliaAnna FranceAjay DhaygudePublished in: BMC nephrology (2021)
This is to the best of our knowledge, the largest series of COVID-19 dialysis patients treated with CPAP in a ward-based setting. In general, dialysis dependent patients have multiple co-morbidities including cardiovascular disease and diabetes mellitus making them vulnerable to COVID-19 and not always suitable for treatment in ICU. We showed a significantly lower 30 day mortality rate with the use of CPAP in the dialysis group (11.1%) compared to the non-dialysis group (78.6%). Despite a small sample size, we believe this study provides impetus for further work clarifying the role of CPAP in treating COVID-19 dialysis dependent patients.
Keyphrases
- end stage renal disease
- chronic kidney disease
- peritoneal dialysis
- sars cov
- cardiovascular disease
- obstructive sleep apnea
- ejection fraction
- newly diagnosed
- healthcare
- type diabetes
- sleep apnea
- positive airway pressure
- adipose tissue
- prognostic factors
- skeletal muscle
- patient reported outcomes
- respiratory syndrome coronavirus
- insulin resistance
- patient reported
- glycemic control